Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimumab + famitinib + chemotherapy in second-line metastatic colorectal cancer
ChiCTR2300076973Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and famitinib in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma, sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300076973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076973.